Hemispherx Biopharma entered into agreement with Defence R&D Canada to evaluate its influenza therapeutic Ampligen® in animal models of human flu. Hemispherx also entered into agreement with National Institute of Infectious Diseases, Japan to assess Ampligen® as an adjuvant to the institute’s nasal flu vaccine.